Like Gilead, Ab­b­Vie gets its ten­ta­cles in­to pact with Ten­tar­ix

The oc­topi at Ten­tar­ix Bio­ther­a­peu­tics are cel­e­brat­ing this morn­ing.

Ab­b­Vie plans to pay $64 mil­lion up­front for two pro­grams out of the San Diego biotech’s so-called Ten­ta­cles plat­form, spread across one tar­get in on­col­o­gy and the oth­er in im­munol­o­gy, the drug de­vel­op­ers said Thurs­day. If the Chica­go-area Big Phar­ma wants to ful­ly ac­quire the pro­grams af­ter the bi­o­log­ic can­di­dates have been nom­i­nat­ed, it will dish out fur­ther pay­ments of undis­closed size.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.